Introduction
Hematopoietic stem cell (HSC) transplantation has been widely and successfully applied to treatments of blood diseases. CCR5 is the key chemokine receptor for HIV virus to enter the targeted human hematopoietic cells 1 . Individuals with a homozygous CCR5 mutation show resistance to HIV-1 infection 2, 3 . The allo-transplantation of HSCs with naturally occurring CCR5 mutation into an HIV-1 patient resulted in a loss of detectable HIV-1 virus 4, 5 . These suggest that transplantation of CCR5 ablated HSCs would be a promising gene therapy approach for HIV-1 cure.
Several studies have shown that Zinc-finger nucleases (ZFNs) could be used to disrupt CCR5 in human CD34+ hematopoietic stem/progenitor cells (HSPCs) despite some off-target cleavage events 6, 7, 8 . Moreover, the CCR5 disrupted HSPCs reconstituted immunodeficient mice show anti-HIV infection and CCR5 disruption enrichment after HIV-1 challenge 6 . CRISPR/Cas9 was recently tried to disrupt CCR5 in hematopoietic progenitor cells 9 . However, CRISPR/Cas9 mediated CCR5 disruption in long-term repopulating HSCs has not been fully illustrated and its HIV-1 prevention effect also remains to be evaluated.
In this study, we established a CRISPR/Cas9 gene-editing and non-viral transfection system in HSPCs with high cleavage efficiency and low off-target effect.
Moreover, we achieved robust CCR5 disruption evaluated in both long-term reconstituted and secondary transplanted mice and observed significant anti-viral effect in vivo.
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Results
Development of Efficient CCR5 Ablation System Based on CRISPR/Cas9 with Minimal Off-target
To efficiently disrupt the human CCR5 gene, we rationally designed and screened a series of sgRNAs targeting the locus from the beginning of first exon to the ∆32 mutation site in human CCR5 gene (Fig. 1A ). These sgRNAs were paired and truncated into 17-18 bp 10 followed by constructing into an optimized scaffold 11 .
Screening with multiple bioinformatic prediction tools 12, 13 was performed to eliminate sgRNAs with high non-specific binding potential and improve the gene editing efficiency. After removing those with high off-target potential, sgRNA pairs were co-nucleofected with Cas9 (Streptococcus pyogenes) into K562 cells to test the cleavage efficiency. Using the selected sgRNA pair, we achieved an average 42% (± 2.1, n = 3) cleavage efficiency in K562 cells, detected using T7 endonuclease I (T7EI) assay (Fig. 1B , representative data) and sequencing.
Then, high-throughput whole genome sequencing (100 ×) was performed to evaluate the non-specific gene targeting in K562 cells. At a genome-wide coverage, we observed only one potential non-specific site chr4:18476075-18476173 , which was not located in an annotated gene coding or functional region. Moreover, no off-target in human CCR2 gene locus was detected in our experiment, which has highly similar sequence to CCR5.
CCR5 Disruption in CD34+ HSPCs without Impairing Differentiation Activity in vitro
Using serum-free culture medium and nucleofection conditions, we achieved CCR5 ablation of 27% (± 5.4, n = 3) in human CD34+ HSPCs in vitro detected using T7EI assay (Fig. 1B) and sequencing. Furthermore, colony-forming unit (CFU) assay was performed to examine the multi-lineage differentiation potential of CD34+ HSPCs after gene editing treatment and various types of colonies ( Fig. 1C) were observed.
Regardless of whether the CCR5 gene editing was performed or not, comparable colony types and numbers ( Fig. 1D ) suggested that colony forming potential was not impacted by gene editing. In addition, we have detected as high as 45% colonies with CCR5 disruption. The percentage of biallelic disruption was 44% in all the edited colonies.
Treated HSPCs produce CCR5 Ablated hematopoietic cells and Multi-lineage progeny in Long-term Reconstituted Mice
To evaluate the CCR5 disruption and the hematopoietic potential, human CD34+
HSPCs with CCR5-ablating treatment were transplanted into NOD/Prkdc scid /IL-2Rγ null (NPG) mice and resulted in rapid and efficient reconstitution in all mice (Fig. 1E ). An average of 8.3% human CD45+ cells engraftment was detected at 12-week post transplantation, which was comparable with control mice transplanted with non-edited
CD34+ cells (Fig. 1F) . To determine the CCR5 editing efficiency, the genomic DNA extracted from the peripheral blood cells of five reconstituted mice at 12-week post transplantation was analyzed using T7EI assay (Fig. 1G) . The average CCR5 cleavage efficiency was 32.2% (± 1.6, n = 5) determined by sequencing.
Long-term HSCs, a rare population of CD34+ cells, support lifetime hematopoiesis by self-renewing and differentiating into all lineages. To confirm whether long-term repopulating HSCs were edited with our strategy, we sampled peripheral blood from 12 mice reconstituted for 30 to 47 weeks and conducted T7EI assay followed by confirmation using Sanger sequencing. The average ablating efficiency at the CCR5 targeting locus was 31.2% (± 4.9%), which was consistent with that of 12-week assay.
Next, we evaluated the multi-lineage reconstitution potential of human gene-edited HSPCs in long-term reconstituted NPG mice. High proportion of human cell chimerism and human CD3+, CD4+ and CD8+ T cells were detected in multiple hematopoietic/immune organs (Figure 2A ), which was comparable with control mice.
In addition, B cells, myeloid cells and NK cells were also observed ( Figure 2B ).
These data indicated that treated HSPCs maintained the activity of long-term hematopoietic repopulating and differentiation into all hematopoietic lineages.
High Proportion of Frameshift Mutations in Disrupted CCR5 Locus
We then tested the ratio of frameshift mutations on human CCR5 locus in peripheral lymphocytes from long-term reconstituted mice, since this type of mutation
has a higher probability to induce protein dysfunction. Sequencing data from the reconstituted mice implied a predictable 35-bp deletion in 107 out of 122 total indel events ( Figure 2C ), confirming a high frequency predictable deletion. The frequency of the CCR5 mutation with frameshift was 95%. These results indicate that CCR5 was efficiently disrupted and most of the alleles were modified with frameshift mutations in our gene editing system.
Robust CCR5 Ablation in Long-term Repopulating HSCs
The gene modification in long-term and secondary reconstituted animal models, instead of short-term reconstitution, reveals the gene editing efficiency in HSCs. We performed secondary transplantation with bone marrow cells derived from long-term (30 to 47 weeks) reconstituted mice at a ratio of 1 to 3. Twelve weeks post transplantation, we euthanized four secondary mice and observed robust human cell reconstitution in bone marrow, peripheral blood, spleen and thymus ( Figure 3A ).
Moreover, we stained bone marrow cells with human CD45 and CD34 markers for FACS analysis. The representative result showed that human HSPCs (CD34+/38-/45RA-/90+) were still present among CD45+ cells ( Figure 3B ), suggesting that CCR5-modified HSPCs were retained in secondary transplanted mice.
The genomic DNA from peripheral blood cells was analyzed by T7EI assay ( Figure   3C ), and the average CCR5 ablation efficiency was 24.7% (± 3.8, n = 9). In addition, gene editing in CD4+ T cells sorted from three secondary transplanted mice was
evaluated. The average CCR5 ablation efficiency in human CD4+ T cells was 27.3%
(± 6.7, n = 3), which was comparable to that of peripheral lymphocyte (25.4% ± 5.9) from the same mice. The result indicated that CCR5 disruption in CD4+ T cells is as efficient as that in peripheral lymphocytes.
The CCR5 disruption in our system remained at high level and robust overtime after transplantation in long-term and secondary transplanted repopulating HSCs ( Figure 3D ). Hence, efficient and robust CCR5 knockout was achieved with our developed system in HSCs that support long-term hematopoiesis.
HIV-1 Challenge in Reconstituted Mice and the Selection Effect
To test the HIV-1 resistance effect, after reconstitution for 10 to 12 weeks, Bal comparable to the previous studies using ZFNs and lentivirus based strategies 6, 15, 22 .
Therefore, CRISPR/Cas9 based CCR5 ablated HSPCs could consistently generate HIV-resisting hematopoietic cells in our system to support stable CD4+ cells count, making our study an evidence for therapeutic potential of CRISPR/Cas9-ablated CCR5 in HSCs for an HIV cure.
In our non-viral CRISPR/Cas9 system targeting CCR5, minimal off-target effect was observed. As the sequence of CCR2 gene has high similarity to that of CCR5, several studies have reported off-target cleavage events in CCR2 when disrupting . However, low off-target level at only one site was observed in a CRISPR mediated CCR5 editing study 9 , which may attribute to the flexible design of sgRNAs in the CRISPR system. To minimize the off-target effect and retain high efficient gene disruption, we adopted optimized sgRNA strategies in our gene editing system, including truncated sgRNA, optimized scaffold and sgRNA pairing strategies 9, 10, 11, 17 . The high throughput whole genome sequencing result showed only one potential non-specific site located in a nonsense region. Although high specificity was detected using genome-wide sequencing, safety concerns of a gene therapy approach should be evaluated in further studies and clinical trials.
Overall, CCR5 ablation was achieved in human long-term HSCs using our high specific CRISPR/Cas9 system and resulted in an apparent HIV-1 resistance. Our 
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Screen of sgRNA pairs
We cloned SpCas9 gene with pCMV promoter and nuclear localization sequence 
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